<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645096</url>
  </required_header>
  <id_info>
    <org_study_id>STU 052018-030</org_study_id>
    <nct_id>NCT03645096</nct_id>
  </id_info>
  <brief_title>Development of Pregnenolone as a Treatment for Depression R61</brief_title>
  <official_title>Development of Pregnenolone as a Treatment for Depression R61</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnenolone, an over-the-counter supplement, is a naturally occurring neurosteroid made in
      the adrenal glands and brain. Preclinical research suggests pregnenolone has antidepressant,
      cognitive enhancing, and neuroprotective properties, particularly in women. The following
      hypothesis will be tested in this trial: pregnenolone is associated with improvement in
      depressive symptom severity in women that is associated with changes in the resting state
      functional connectivity (rsFC) and GABA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 26 adult women meeting criteria for Major Depressive Disorder (MDD) as defined
      in DSM 5, will be randomized to a double-blind, placebo-controlled, crossover phase I
      clinical trial of pregnenolone (i.e. each participant receives 500 mg/d, 800 mg/d
      pregnenolone and placebo in random order). The study will consist of three 7-day treatment
      exposures to each pregnenolone dose with a 14-day washout between each exposure. Baseline
      evaluation will include medical and psychiatric history, psychiatric interview, standard
      laboratory analyses (i.e., blood draw, ECG), and a brief cognitive battery. Neuroimaging will
      be collected after each study drug or placebo administration. Study drug tolerability and
      participant safety will be assessed throughout the study (6 in-clinic visits + a safety
      visit) using structured clinical interviews, self-report questionnaires, and standard
      laboratory analyses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional connectivity.</measure>
    <time_frame>7 days</time_frame>
    <description>Amygdala—PCC or dlPFC—insula functional connectivity using structural neuroimaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GABA concentration.</measure>
    <time_frame>7 days</time_frame>
    <description>Occipital GABA concentration using spectroscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Events (SAFTEE).</measure>
    <time_frame>7 days</time_frame>
    <description>SAFTEE is a side effect self-report assessment scale that consists of 56 potential side effects. Participants rate how bothersome each side effect is on a scale of &quot;none&quot; (0), &quot;mild&quot; (1), &quot;moderate&quot; (2), &quot;severe&quot; (3). The higher total score (all items summed together) indicates a higher level of side effect burden.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum pregnenolone level.</measure>
    <time_frame>7 days</time_frame>
    <description>Measure blood serum pregnenolone and allopregnanolone levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnenolone dose.</measure>
    <time_frame>7 days</time_frame>
    <description>Identify a dose of pregnenolone that demonstrates bioavailabilit and tolerability.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Pregnenolone 500 &gt; Pregnenolone 800 &gt; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Matching placebo capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnenolone 500 &gt; Placebo &gt; Pregnenolone 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 800 mg capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnenolone 800 &gt; Pregnenolone 500 &gt; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Matching placebo capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnenolone 800 &gt; Placebo &gt; Pregnenolone 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 500 mg capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &gt; Pregnenolone 500 &gt; Pregnenolone 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 500 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 800 mg capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &gt; Pregnenolone 800 &gt; Pregnenolone 500</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 exposures in order:
Matching placebo capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 800 mg capsule by mouth, daily for 7 days followed by 14 day washout.
Pregnenolone 500 mg capsule by mouth, daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone 500 mg</intervention_name>
    <description>Pregnenolone 500 mg capsule.</description>
    <arm_group_label>Placebo &gt; Pregnenolone 500 &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Placebo &gt; Pregnenolone 800 &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Placebo &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Pregnenolone 800 &gt; Placebo</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Placebo &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Pregnenolone 500 &gt; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone 800 mg</intervention_name>
    <description>Pregnenolone 800 mg capsule.</description>
    <arm_group_label>Placebo &gt; Pregnenolone 500 &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Placebo &gt; Pregnenolone 800 &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Placebo &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Pregnenolone 800 &gt; Placebo</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Placebo &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Pregnenolone 500 &gt; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule manufactured to mimic pregnenolone capsule.</description>
    <arm_group_label>Placebo &gt; Pregnenolone 500 &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Placebo &gt; Pregnenolone 800 &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Placebo &gt; Pregnenolone 800</arm_group_label>
    <arm_group_label>Pregnenolone 500 &gt; Pregnenolone 800 &gt; Placebo</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Placebo &gt; Pregnenolone 500</arm_group_label>
    <arm_group_label>Pregnenolone 800 &gt; Pregnenolone 500 &gt; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, ages 18-65 years, with current MDD (mild or moderate severity per DSM-5) based
             on SCID-CV.

          -  No psychotropic medications, other than PRN (as needed) hypnotics, within 28 days of
             randomization (medication free).

          -  PRN hypnotics allowed up to 3 days prior to study drug administrations but not while
             receiving study drug.

        Exclusion Criteria:

          -  Severe MDD based on DSM-5 severity criteria and/or a baseline HRSD score &gt; 27
             (consistent with severe depressive symptom severity).

          -  High risk for suicide (active SI with plan/intent or &gt; 2 lifetime attempts in lifetime
             or any in the past 6 months).

          -  Treatment resistant depression (fail two adequate antidepressant trials or ECT during
             current episode).

          -  Vulnerable populations (e.g. pregnant/nursing, severe cognitive or intellectual
             impairment, incarcerated).

          -  Coronary artery disease, atrial fibrillation, stroke, deep vein thrombosis, pulmonary
             embolism or blood clotting disorder, or any severe, life threatening or unstable,
             medical condition.

          -  History of allergic reaction or side effects with prior pregnenolone use.

          -  Current substance use disorder defined as meeting criteria for a use disorder based on
             the SCID interview and self-reported use within the past 3 months, or a positive
             baseline urine drug screen.

          -  Current psychotic features (hallucinations, delusions, disorganized thought processes)
             or eating disorders.

          -  Anxiety disorders of sufficient severity to be the primary focus of clinical attention
             (e.g. severe obsessive compulsive or post-traumatic stress disorders).

          -  Hormone-sensitive conditions (i.e. breast cancer; uterine/ovarian cancer,
             endometriosis, uterine fibroids).

          -  Clinically significant laboratory, physical examination, or electrocardiogram (ECG)
             findings.

          -  Currently using oral contraceptives containing progestin (barrier methods allowed).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherwood Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Kulikova, MS</last_name>
    <phone>2146456967</phone>
    <email>alexandra.kulikova@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherwood Brown, MD, PhD</last_name>
    <phone>2146456950</phone>
    <email>sherwood.brown@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Kulikova, MS</last_name>
    </contact>
    <contact_backup>
      <phone>2146456967</phone>
      <email>alexandra.kulikova@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sherwood Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Sherwood Brown, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Pregnenolone</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

